AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
zileuton 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5-lipo-oxygenase inhibitors, anti-inflammatory | 2862 | 111406-87-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
an orally active inhibitor of 5-lipoxygenase, the enzyme that catalyzes the formation of leukotrienes from arachidonic acid
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.14 mg/mL | Bocci G, Oprea TI, Benet LZ |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 169.28 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 2.138 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.543 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 62.373 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 9.376 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 9.640 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 15.280 | % | High | 1 |
| herg | hERG pIC50 | 4.334 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 6.427 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 5.572 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 10.090 | % | High | 1 |
| kinase-safety-class | ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,PDK1,PDK2,PDK4,PIK3CB,PRKDC | 17 | |||
| kinase-selectivity-class | AXL,DYRK1B,GRK2,STK33 | 4 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 2.871 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 45.604 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 10.490 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 5.140 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 0 | High | 1 | |
| pppb | Pig plasma protein binding (% unbound) | 20.790 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 26.485 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 73.900 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 8.380 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 353.997 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 9, 1996 | FDA | CHIESI USA INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Asthma | 50.93 | 37.44 | 25 | 459 | 242135 | 90385828 |
| Anaphylactic reaction | 37.72 | 37.44 | 15 | 469 | 87509 | 90540454 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Asthma | 40.30 | 31.88 | 19 | 378 | 250272 | 110338630 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| FDA PE | N0000008683 | Decreased Leukotriene Production |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D006727 | Hormone Antagonists |
| MeSH PA | D016859 | Lipoxygenase Inhibitors |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018501 | Antirheumatic Agents |
| MeSH PA | D018689 | Sensory System Agents |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| MeSH PA | D020024 | Leukotriene Antagonists |
| FDA MoA | N0000175955 | 5-Lipoxygenase Inhibitors |
| FDA EPC | N0000175956 | 5-Lipoxygenase Inhibitor |
| CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory drug |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:49159 | leukotriene antagonist |
| CHEBI has role | CHEBI:49167 | anti-asthmatic drug |
| CHEBI has role | CHEBI:64964 | EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor |
| CHEBI has role | CHEBI:65023 | anti-asthmatic agent |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
| CHEBI has role | CHEBI:173084 | ferroptosis inhibitor |
| CHEBI has role | CHEBI:233423 | antifibrotic agent |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Non-allergic asthma | indication | 266361008 | DOID:9360 |
| Allergic asthma | indication | 389145006 | DOID:9415 |
| Asthma management | indication | 406162001 | |
| Suicidal thoughts | contraindication | 6471006 | |
| Hallucinations | contraindication | 7011001 | |
| Mood swings | contraindication | 18963009 | |
| Feeling agitated | contraindication | 24199005 | |
| Depressive disorder | contraindication | 35489007 | |
| Anxiety | contraindication | 48694002 | |
| Dream disorder | contraindication | 85418005 | |
| Liver function tests abnormal | contraindication | 166603001 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Tremors | contraindication | ||
| Nervousness | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.96 | acidic |
| pKa2 | 13.02 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Arachidonate 5-lipoxygenase | Enzyme | INHIBITOR | IC50 | 6.52 | CHEMBL | CHEMBL | |||
| Arachidonate 15-lipoxygenase | Enzyme | IC50 | 6.40 | CHEMBL | |||||
| Cysteinyl leukotriene receptor 2 | GPCR | IC50 | 5.82 | WOMBAT-PK | |||||
| Leukotriene A-4 hydrolase | Enzyme | IC50 | 6.07 | WOMBAT-PK | |||||
| Leukotriene B4 receptor 1 | GPCR | IC50 | 6.38 | CHEMBL | |||||
| Arachidonate 5-lipoxygenase-activating protein | Cytosolic other | IC50 | 5.66 | CHEMBL | |||||
| Bifunctional epoxide hydrolase 2 | Enzyme | IC50 | 6.23 | CHEMBL | |||||
| Prostaglandin E synthase | Enzyme | IC50 | 6.22 | CHEMBL | |||||
| Protein-lysine 6-oxidase | Enzyme | IC50 | 5.46 | CHEMBL | |||||
| Arachidonate 5-lipoxygenase | Enzyme | IC50 | 6.85 | CHEMBL | |||||
| Arachidonate 5-lipoxygenase | Enzyme | IC50 | 6.72 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4021009 | VUID |
| N0000148478 | NUI |
| D00414 | KEGG_DRUG |
| 4021009 | VANDF |
| C0081408 | UMLSCUI |
| CHEBI:10112 | CHEBI |
| CHEMBL93 | ChEMBL_ID |
| DB00744 | DRUGBANK_ID |
| 60490 | PUBCHEM_CID |
| C063449 | MESH_SUPPLEMENTAL_RECORD_UI |
| 5297 | IUPHAR_LIGAND_ID |
| 6595 | INN_ID |
| V1L22WVE2S | UNII |
| 40575 | RXNORM |
| 254934 | MMSL |
| 5704 | MMSL |
| d04103 | MMSL |
| 006297 | NDDF |
| 108617005 | SNOMEDCT_US |
| 386180009 | SNOMEDCT_US |
| V1L22WVE2S | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| ZYFLO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10122-901 | TABLET | 600 mg | ORAL | NDA | 14 sections |
| Zileuton | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-044 | TABLET, FILM COATED, EXTENDED RELEASE | 600 mg | ORAL | ANDA | 25 sections |
| Zileuton | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-741 | TABLET, MULTILAYER, EXTENDED RELEASE | 600 mg | ORAL | ANDA | 17 sections |
| Zileuton | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64380-189 | TABLET, MULTILAYER, EXTENDED RELEASE | 600 mg | ORAL | ANDA | 16 sections |
| Zileuton | Human Prescription Drug Label | 1 | 64980-206 | TABLET, EXTENDED RELEASE | 600 mg | ORAL | ANDA | 17 sections |
| ZILEUTON | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-169 | TABLET, EXTENDED RELEASE | 600 1 | ORAL | ANDA | 24 sections |
| Zileuton | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72603-246 | TABLET, FILM COATED, EXTENDED RELEASE | 600 mg | ORAL | ANDA | 25 sections |